Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Roche Products (India) Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written informed consent. 2. Male and female patients of NSCLC/SCLC, more than equal to 18 years of age. 3. Patients who have been prescribed Tecentriq for the medical management in routine clinical practice according to the standard of care and in line with the current Indian prescribing information (local label). Patients who have received less than equal to 3 cycle of Tecentriq therapy at screening visit.
Exclusion criteria
Exclusion criteria: 1. Patients not receiving treatment for lung cancer with Tecentriq according to standard of care and in line with the current prescribing information. 2. Known or suspected hypersensitivity to Tecentriq 3. Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the overall survival (OS) at two years in patients who receive Tecentriq for the treatment of lung cancer in routine clinical practice. The OS will be estimated separately for the first-line metastatic non-small cell lung cancer (1LmNSCLC), adjuvant NSCLC, and first-line extensive-stage small cell lung cancer (1LES SCLC).Timepoint: OS at two years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To estimate PFS in patients treated with Tecentriq for metastatic lung cancer (1L mNSCLC, 1L ES SCLC) & DFS in those treated with Tecentriq in an adjuvant NSCLC setting in routine clinical practice. 2. To estimate the ORR, DCR, & DoR in patients who receive Tecentriq for the treatment of approved indications in metastatic setting (1L mNSCLC, 1L ES SCLC) in routine clinical practice. 3. To evaluate the Safety of Atezolizumab for the treatment of lung cancer (NSCLC & SCLC) in routine clinical practices on the basis of the following endpoint: Incidence, nature, & severity of all AEs, SAEs, & AESIs according to NCI CTCAE v5.0. 4. To estimate the proportion of patients who are prescribed Tecentriq & undergo PD-L1 testing & molecular testing in routine clinical practice along with details on the assay type & results. 5. To evaluate the association between patient characteristics & treatment outcomes in routine clinical practice.Timepoint: From the date of start of Tecentriq therapy to the first date of objectively determined response or death from any cause | — |
Countries
India
Contacts
Public ContactDr Jaishid Ahdal
Roche Products (India) Pvt. Ltd.
Outcome results
None listed